Aptose reports FY 2024 net loss of $25.4M; cash runway to April 2025

Aptose Biosciences Inc.

Net loss $25.4M vs $51.2M in FY 2023; diluted EPS ($36.38) vs ($227.43).
Cash and equivalents $6.7M as of Dec 31, 2024; expect funding through April 2025.
TUS+VEN+AZA triplet TUSCANY trial advancing; 40mg achieved CRs; 80mg dosing started.
$1.5M of Hanmi debt converted to 409,063 common shares; Hanmi stake capped at 19.99%.
Regained Nasdaq minimum bid compliance; still not in compliance with $2.5M equity requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.